Table 4.
Patterns of first recurrence according to the 2016 WHO classification and extent of resection.
| Recurrence | Type of recurrence | |||
|---|---|---|---|---|
| Infield GTV | Infield CTV/marginal | Outfield/CSF seeding | ||
| All | 31 | 20 | 6 | 5 |
| 2016 WHO classification | ||||
| AO, IDH-mutant and 1p/19q-codeleted (n = 25) | 3 (12.0%) | 2 | 0 | 1 |
| GTR (n = 17) | 0 (0.0%) | 0 | 0 | 0 |
| STR (n = 7) | 2 (28.6%) | 1 | 0 | 1 |
| PR-Bx (n = 1) | 1 (100.0%) | 1 | 0 | 0 |
| AA, IDH-mutant (n = 11) | 5 (45.5%) | 4 | 1 | 0 |
| GTR (n = 6) | 1 (16.7%) | 0 | 1 | 0 |
| STR (n = 2) | 2 (100%) | 2 | 0 | 0 |
| PR-Bx (n = 3) | 2 (66.7%) | 2 | 0 | 0 |
| AA, IDH-wildtype (n = 37) | 23 (62.2%) | 14 | 5 | 4 |
| GTR (n = 20) | 12 (60.0%) | 6 | 5 | 1 |
| STR (n = 9) | 4 (44.4%) | 4 | 0 | 0 |
| PR-Bx (n = 8) | 7 (87.5%) | 4 | 0 | 3 |
| Extent of resection | ||||
| GTR (n = 43) | 13 (30.2%) | 6 | 6 | 1 |
| STR (n = 18) | 8 (44.4%) | 7 | 0 | 1 |
| PR-Bx (n = 12) | 10 (83.3%) | 7 | 0 | 3 |
The numbers represent the number of patients with recurrences. Column 2 represents the number of patients in each subgroup with recurrence and their percentages are indicated in parentheses. GTV, Gross Tumor Volume; CTV, Clinical Target Volume; CSF, Cerebrospinal Fluid; WHO, World Health Organization; AO, Anaplastic Oligodendroglioma; IDH, isocitrate dehydrogenase gene; GTR, Gross Total Resection; STR, Subtotal Resection; PR, Partial Resection; Bx, Biopsy; AA, Anaplastic Astrocytoma.